Anshan Hifichem Co., Ltd.
SZSE:300758.SZ
9.66 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,217.822 | 1,208.553 | 1,346.896 | 1,008.303 | 694.585 | 610.949 | 552.75 | 441.98 | 369.52 | 322.714 |
| Cost of Revenue
| 899.657 | 892.278 | 921.106 | 650.766 | 433.602 | 396.752 | 350.094 | 287.69 | 252.348 | 236.383 |
| Gross Profit
| 318.165 | 316.275 | 425.79 | 357.538 | 260.982 | 214.197 | 202.656 | 154.29 | 117.172 | 86.331 |
| Gross Profit Ratio
| 0.261 | 0.262 | 0.316 | 0.355 | 0.376 | 0.351 | 0.367 | 0.349 | 0.317 | 0.268 |
| Reseach & Development Expenses
| 81.249 | 90.973 | 81.733 | 51.227 | 31.108 | 24.791 | 42.865 | 34.629 | 29.211 | 12.686 |
| General & Administrative Expenses
| 39.171 | 77.639 | 33.407 | 21.327 | 16.392 | 10.016 | -27.481 | -24.428 | -22.886 | 4.375 |
| Selling & Marketing Expenses
| 45.153 | 47.914 | 50.544 | 32.17 | 36.962 | 33.019 | 27.555 | 20.355 | 18.729 | 14.705 |
| SG&A
| 84.324 | 125.553 | 83.951 | 53.497 | 53.354 | 43.035 | 0.074 | -4.073 | -4.157 | 19.08 |
| Other Expenses
| -3.131 | -3.145 | 25.836 | 2.803 | -32.689 | -1.301 | 8.009 | 6.432 | 16.622 | 5.018 |
| Operating Expenses
| 265.408 | 287.415 | 225.982 | 140.954 | 112.31 | 88.736 | 74.278 | 63.44 | 58.182 | 47.989 |
| Operating Income
| 11.259 | 0.771 | 208.371 | 207.968 | 154.673 | 120.633 | 121.884 | 87.198 | 42.994 | 16.148 |
| Operating Income Ratio
| 0.009 | 0.001 | 0.155 | 0.206 | 0.223 | 0.197 | 0.221 | 0.197 | 0.116 | 0.05 |
| Total Other Income Expenses Net
| -3.131 | -4.311 | 12.551 | 3.21 | -32.274 | -1.301 | -0.06 | 0.814 | 2.221 | 5.015 |
| Income Before Tax
| 8.127 | -3.54 | 220.922 | 211.178 | 122.4 | 119.332 | 121.824 | 88.013 | 45.215 | 21.162 |
| Income Before Tax Ratio
| 0.007 | -0.003 | 0.164 | 0.209 | 0.176 | 0.195 | 0.22 | 0.199 | 0.122 | 0.066 |
| Income Tax Expense
| -8.961 | -14.853 | 20.678 | 25.659 | 14.3 | 13.955 | 18.439 | 12.343 | 6.389 | 2.987 |
| Net Income
| 11.002 | -2.774 | 179.972 | 175.456 | 108.099 | 105.377 | 103.384 | 75.67 | 38.826 | 18.175 |
| Net Income Ratio
| 0.009 | -0.002 | 0.134 | 0.174 | 0.156 | 0.172 | 0.187 | 0.171 | 0.105 | 0.056 |
| EPS
| 0.027 | -0.007 | 0.46 | 0.54 | 0.33 | 0.43 | 0.42 | 0.31 | 0.16 | 0.072 |
| EPS Diluted
| 0.027 | -0.007 | 0.46 | 0.54 | 0.33 | 0.43 | 0.42 | 0.31 | 0.16 | 0.072 |
| EBITDA
| 199.146 | 167.862 | 318.261 | 279.188 | 161.502 | 156.788 | 164.62 | 134.55 | 110.923 | 47.666 |
| EBITDA Ratio
| 0.164 | 0.139 | 0.236 | 0.277 | 0.233 | 0.257 | 0.298 | 0.304 | 0.3 | 0.148 |